Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

PHASE I

Inclusion Criteria (phase I):

   - Women must not be pregnant or breastfeeding; breastfeeding must be discontinued or the
   subject is not eligible for the study

   - All females of childbearing potential must have a blood test within 2 weeks prior to
   randomization to rule out pregnancy; a female of childbearing potential is any woman,
   regardless of sexual orientation or whether they have undergone tubal ligation, who
   meets the following criteria: 1) has not undergone a hysterectomy or bilateral
   oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive
   months (i.e., has had menses at any time in the preceding 24 consecutive months)

   - Women of childbearing potential and sexually active males must be strongly advised to
   use an accepted and effective method of contraception

   - Patients must have histologically or cytologically confirmed:

      - Extensive stage small cell lung cancer (SCLC) or

      - Stage IV (M1a or M1b according to American Joint Committee on Cancer [AJCC]
      Staging Manual, 7th edition) large cell neuroendocrine non-small cell lung cancer
      (NSCLC) or

      - Small cell carcinoma of unknown primary or extrapulmonary origin and must be a
      candidate for systemic therapy

         - NOTE: The extensive disease SCLC classification for this protocol includes
         all patients with disease sites not defined as limited stage; limited stage
         disease category includes patients with disease restricted to one hemithorax
         with regional lymph node metastases, including hilar, ipsilateral and
         contralateral mediastinal, and/or ipsilateral supraclavicular nodes;
         extensive disease patients are defined as those patients with extrathoracic
         metastatic disease, malignant pleural effusion, bilateral or contralateral
         supraclavicular adenopathy

   - Patients must have measurable or non-measurable disease based on Response Evaluation
   Criteria in Solid Tumors (RECIST) 1.1; baseline measurements and evaluations of all
   sites of disease must be obtained =< 4 weeks prior to registration (Phase I)

   - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

   - Absolute neutrophil count >= 1,500/mm^3

   - Platelets >= 100,000/mm^3

   - Leukocytes >= 3,000/mm^3

   - Hemoglobin >= 9 g/dL

   - Total bilirubin =< 1.5 times institutional upper limit of normal (ULN)

   - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
   alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase[SGPT]) =< 3
   times institutional ULN (=< 5 times if liver function test [LFT] elevations due to
   known liver metastases)

   - Creatinine =< 1.5 X ULN OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients
   with creatinine levels > 1.5 x ULN

   - Patients with central nervous system (CNS) metastases or a history of CNS metastases
   are ineligible

   - Patients cannot have had prior chemotherapy or biologic therapy for SCLC or large cell
   neuroendocrine NSCLC, or small cell carcinoma of unknown primary or extrapulmonary
   origin; patients receiving prior radiation cannot register within 7 days after
   completion of radiation, and must have resolved adverse events attributed to radiation
   to =< grade 1; no previous irradiation to the only site of measurable or evaluable
   disease, unless that site had subsequent evidence of progression

   - Patients receiving prior radiation cannot register within 7 days after completion of
   radiation, and must have resolved adverse events attributed to radiation to =< grade
   1; no previous irradiation to the only site of measurable or evaluable disease, unless
   that site had subsequent evidence of progression

   - Patients must NOT have uncontrolled intercurrent illness including, but not limited
   to, ongoing or active infection, symptomatic congestive heart failure, unstable angina
   pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations
   that would limit compliance with study requirements

   - Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
   therapy are ineligible

   - Patient must be able to swallow pills

Exclusion Criteria (phase I):

   - Patients have active seizure(s) or history of seizure(s)

   - Patients have history of allergic reactions attributed to compounds of similar
   chemical or biologic composition to veliparib or other agents used in the study

PHASE II

Inclusion Criteria (phase II):

   - Women must not be pregnant or breastfeeding; breastfeeding must be discontinued or the
   subject is not eligible for the study

   - All females of childbearing potential must have a blood test within 2 weeks prior to
   randomization to rule out pregnancy; a female of childbearing potential is any woman,
   regardless of sexual orientation or whether they have undergone tubal ligation, who
   meets the following criteria: 1) has not undergone a hysterectomy or bilateral
   oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive
   months (i.e., has had menses at any time in the preceding 24 consecutive months) with
   the current month counted as month 1

   - Women of childbearing potential and sexually active males must be strongly advised to
   use an accepted and effective method of contraception

   - Patients must have extensive stage, histologically or cytologically confirmed small
   cell lung cancer; NOTE: the extensive disease classification for this protocol
   includes all patients with disease sites not defined as limited stage; limited stage
   disease category includes patients with disease restricted to one hemithorax with
   regional lymph node metastases, including hilar, ipsilateral and contralateral
   mediastinal, and/or ipsilateral supraclavicular nodes; extensive disease patients are
   defined as those patients with extrathoracic metastatic disease, malignant pleural
   effusion, bilateral or contralateral supraclavicular adenopathy

   - Patients must have measurable disease based on RECIST 1.1; baseline measurements and
   evaluations of all sites of disease must be obtained =< 4 weeks prior to registration

   - ECOG performance status 0 or 1

   - Absolute neutrophil count >= 1,500/mm^3

   - Platelets >= 100,000/mm^3

   - Leukocytes >= 3,000/mm^3

   - Hemoglobin >= 9 g/dL

   - Total bilirubin =< 1.5 times institutional upper limit of normal (ULN)

   - AST (SGOT) and ALT (SGPT) =< 3 times institutional ULN (=< 5 times if LFT elevations
   due to known liver metastases)

   - Creatinine =< 1.5 X ULN OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients
   with creatinine levels > 1.5 x ULN

   - Patients cannot have had prior chemotherapy or biologic therapy for small cell lung
   cancer; patients receiving prior radiation cannot register within 7 days after
   completion of radiation, and must have resolved adverse events attributed to radiation
   to =< grade 1; no previous irradiation to the only site of measurable or evaluable
   disease, unless that site had subsequent evidence of progression

   - Patient must be able to swallow pills

   - Patients may not be receiving any other investigational agents while on study

Exclusion Criteria (phase II):

   - Patients with CNS metastases or a history of CNS metastases are ineligible

   - Patients have history of allergic reactions attributed to compounds of similar
   chemical or biologic composition to veliparib or other agents used in the study

   - Patients have active seizure(s) or history of seizure(s)

   - Patients must NOT have uncontrolled intercurrent illness including, but not limited
   to, ongoing or active infection, symptomatic congestive heart failure, unstable angina
   pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations
   that would limit compliance with study requirements

   - HIV-positive patients on combination antiretroviral therapy are ineligible because of
   the potential for pharmacokinetic interactions with veliparib; in addition, these
   patients are at increased risk of lethal infections when treated with
   marrow-suppressive therapy; appropriate studies will be undertaken in patients
   receiving combination antiretroviral therapy when indicated